Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT07725796 is registered in ClinicalTrials.gov with UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. as lead sponsor.

NCT NCT07725796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07725796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-501 Administered Intravesically in Adult Participants With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
Lead sponsor
UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 28, 2026
Completion date
August 2, 2029
Enrollment
30 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer, nmibc, non-muscle invasive bladder cancer (nmibc), non-muscle invasive bladder carcinoma, urothelial carcinoma bladder, urothelial carcinoma in situ, urothelial carcinoma of the urinary bladder, urothelial carcinoma recurrent